ArticleFrontiers in psychiatry2025
What do patients with substance use disorders know about their medication? A cross-sectional interview-based study.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-World Pharmacological Management of Alcohol Dependence in a Nepalese Rehabilitation Center: Prospective Cohort Study.Public health challenges · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study investigates the medication knowledge of patients with substance use disorders (SUDs) treated at a psychiatric clinic in northern Germany, aiming to identify gaps in understanding and to enhance patient safety, particularly concerning ATC group A drugs. Setting: The study was conducted in the Department of Psychiatry, Social Psychiatry, and Psychotherapy at Hannover Medical School, Germany. Design: A cross-sectional, interview-based study using a convenience sample of 100 patients was conducted between March 2023 and April 2024. Participants: The cohort included patients with SUDs who had been hospitalized for at least 72 hours, regularly took at least one medication in addition to withdrawal drugs, and who displayed no cognitive impairments. Participants had a median age of 46.5 years; 62% were male. Intervention: Patients were interviewed using a customized questionnaire addressing knowledge of drug name, indication, dosage, and frequency of application. The questionnaire also assessed the sources of medication knowledge and patient opinions on their medication regimen. Primary and secondary outcome measures: The primary outcome was the average medication knowledge score (range 0-6). Secondary measures included differences in knowledge across drug groups, sources of information, and demographic influences. Results: The median medication knowledge score was 3.8 out of 6. Knowledge was significantly lower for ATC group A drugs compared to groups B, C, and N (p < 0.001). No significant differences were observed between men and women nor between age groups. Hospital physicians were the primary information source for 40% of patients. Most participants (84%) considered their medication regimen adequate. Conclusion: Patients with SUDs demonstrated suboptimal medication knowledge, particularly regarding ATC group A drugs. Future strategies should prioritize patient education and enhanced physician engagement to improve understanding and adherence, ultimately fostering better therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.